The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAMYT.L Regulatory News (AMYT)

  • There is currently no data for AMYT

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Corporate Update

1 Jun 2015 07:00

RNS Number : 7164O
Fastnet Oil & Gas PLC
01 June 2015
 

1 June 2015

Fastnet Oil & Gas plc

("Fastnet" or the "Company")

 

Corporate Update

 

Fastnet (AIM: FAST, ESM: FOI), the UK and Irish listed E&P company focused on near-term exploration and appraisal acreage in Morocco and the Celtic Sea, provides the following corporate update.

 

Highlights:

Significant reduction in G&A, with overhead down over 40% since the end of 2014, with further reductions expected.Cash on the balance sheet of USD$16.2 million at 31 May 2015.The Company continues to evaluate M&A opportunities capable of delivering significant shareholder value.Discussions have commenced with the Department of Communications, Energy and Natural Resources following the expiration of licensing options on 31 May 2015 of 12/2 ("Molly Malone") and 12/3 ("Mizzen").Applications have been submitted for new licensing options over high-graded portions of the previous Mizzen and Molly license areas.

 

Corporate

Fastnet provides the following update on the Molly Malone and Mizzen licensing options in the Celtic Sea (together the "Options"). In the absence of Fastnet having committed to certain additional obligations including drilling, the Options expired on 31 May 2015.

Fastnet has today submitted applications for new licensing options over portions of the original licensing option areas. The new licensing option areas were high-graded based on the technical evaluation carried out since the original licensing options were first awarded. The Minister of State at the Department of Communications, Energy and Natural Resources will consider applications received in respect of these areas in the coming months and the Company will provide an update on this process when more information is available. 

Fastnet remains excited by the quality of its Celtic Sea portfolio and will continue to technically evaluate and high-grade its acreage in the Celtic Sea. Numerous prospects and leads have been extensively mapped over the last 6 months based on newly acquired and reprocessed seismic data throughout the currently held option areas. The Company is in the process of compiling new resource estimates for the portfolio of prospects and leads.

The Company also continues to evaluate M&A opportunities in the current market environment which will deliver significant shareholder value while focussing on developing its Celtic Sea portfolio.

 

Financial

The Company has undergone a comprehensive review of general and administration costs and has reduced overheads by over 40% since December 2014 to $1.9m a year. Further corporate and overhead costs reductions are ongoing.

The Company's cash balance at 31 May 2015 was $16.2 million.

 

Carol Law, CEO of Fastnet, commented:

"We have been conducting detailed due diligence on a number of merger and acquisition opportunities in the sector, but as of yet have not identified one which would be accretive to shareholders and therefore be a suitable use of our available cash. We have taken steps to preserve our cash through reducing ongoing costs and have nearly halved our G&A expenses since the end of 2014. In the immediate future we will continue to scrutinize costs to further reduce overhead and evaluate targeted merger and acquisition opportunities aimed at enhancing value for our shareholders."

 

For further information please contact:

Fastnet Oil & Gas plc

+353 (1) 644 0007

Carol Law, Chief Executive Officer

 

Cathal Friel, Non-Executive Chairman

 

 

 

Shore Capital

+44 (0) 20 7408 4090

Nomad

 

Bidhi Bhoma, Edward Mansfield

 

 

 

Corporate Broking

 

Jerry Keen

 

 

 

Davy

+353 (1) 679 6363

(ESM Adviser & Joint Broker)

 

John Frain, Anthony Farrell

 

 

 

Camarco

+44 (0) 20 3757 4980

Billy Clegg, Georgia Mann

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCSEIFMUFISESI
Date   Source Headline
4th Mar 202112:00 pmRNSAmryt Announces Record FY 2020 Results
25th Feb 20217:00 amRNSAmryt Supports Global Rare Disease Day 2021
24th Feb 20217:00 amGNWAmryt to Announce Q4 and FY 2020 Results on Thursday March 4, 2021
10th Feb 20217:00 amRNSAmryt to Present at SVB Leerink Conference
4th Feb 20217:00 amGNWAmryt and Medison Pharma Sign Multi-Regional Distribution Agreements in Canada and Israel
20th Jan 20217:00 amGNWAmryt Receives Reimbursement Approval from NICE for Myalepta® (metreleptin) in England and Wales
6th Jan 20217:00 amRNSAmryt to present at H.C Wainwright Conference
23rd Dec 20207:00 amGNWAmryt Granted Orphan Drug Designation by the FDA for AP103
17th Dec 20207:00 amGNWAmryt Receives Ministry of Health Reimbursement Approval for Lojuxta® (lomitapide) in Saudi Arabia
11th Dec 202010:00 amGNWHolding(s) in Company
9th Dec 20202:45 pmGNWHolding(s) in Company
9th Dec 20207:00 amGNWAmryt Group Receives Marketing Authorisation Approval for Lojuxta® in Brazil
8th Dec 20207:00 amGNWAmryt Announces $40m Private Placement with Leading Biotech Investors
5th Nov 202012:00 pmGNWAmryt Reports Record Q3 2020 Results - Raising FY 2020 Revenue Guidance
29th Oct 20207:00 amGNWAMRYT ANNOUNCES POSITIVE RESULTS FROM PHASE 3 TRIAL OF FILSUVEZ® IN EPIDERMOLYSIS BULLOSA
19th Oct 20207:00 amGNWAmryt and Swixx Sign Distribution Deal for Lojuxta
14th Oct 20207:00 amRNSAMRYT TO ANNOUNCE Q3 RESULTS ON NOVEMBER 5, 2020
14th Oct 20207:00 amGNWNotice of Results
12th Oct 202011:00 amGNWHolding(s) in Company
9th Oct 20207:00 amGNWVirtual Analyst & Investor Event - Tuesday November 3, 2020
8th Oct 20207:00 amGNWAMRYT TO PRESENT EASE TRIAL DATA BY LATE-BREAKING PRESENTATION AT EADV ON OCTOBER 31, 2020
1st Oct 20207:00 amGNWExercise of Options and Total Voting Rights
30th Sep 202012:30 pmGNWHolding(s) in Company
23rd Sep 20207:00 amRNSAMRYT SUPPORTS GLOBAL FH AWARENESS DAY
21st Sep 202011:00 amGNWExercise of Warrants & Issue of Ordinary Shares and Total Voting Rights
15th Sep 20207:00 amRNSPOSITIVE OPINION ON AP103 ORPHAN DRUG DESIGNATION
9th Sep 20202:05 pmRNSSecond Price Monitoring Extn
9th Sep 20202:00 pmRNSPrice Monitoring Extension
9th Sep 20207:00 amRNSPOSITIVE TOP LINE RESULTS FROM PHASE 3 TRIAL IN EB
11th Aug 202011:09 amRNSCANCELLATION OF ADMISSION TO EURONEXT GROWTH
7th Aug 20207:00 amRNSAMRYT PRESENTING AT CANACCORD GENUITY CONFERENCE
6th Aug 202012:00 pmRNSAMRYT ANNOUNCES Q2 2020 RESULTS
29th Jul 20202:30 pmRNSResult of AGM
29th Jul 20207:00 amRNSAMRYT HOSTING KOL CALL ON EB DISEASE LANDSCAPE
20th Jul 20207:00 amRNSAMRYT TO ANNOUNCE Q2 RESULTS ON AUGUST 6, 2020
15th Jul 20208:00 amRNSEuronext Growth Dublin Notice
10th Jul 20207:00 amRNSExercise of Warrants & Issue of Ordinary Shares
8th Jul 20203:09 pmRNSAMRYT LISTED ON NASDAQ & CEO TO RING CLOSING BELL
30th Jun 20207:00 amRNSPOSTING OF ANNUAL REPORT AND NOTICE OF AGM
24th Jun 20207:00 amRNSForm F-1 publicly filed for impending US listing
4th Jun 20202:20 pmRNSDirector/PDMR Shareholding
3rd Jun 202011:30 amRNSDirector/PDMR Shareholding
3rd Jun 20207:00 amRNSAMRYT & SWIXX SIGN DISTRIBUTION DEAL FOR MYALEPTA
11th May 20207:00 amRNSQ1 2020 RESULTS
11th May 20207:00 amRNSFY 2019 RESULTS
7th May 20209:00 amRNSNotice of Results
7th May 20207:00 amRNSFILSUVEZ® CONFIRMED AS GLOBAL BRAND NAME FOR AP101
23rd Apr 20207:00 amRNSEASE CLINICAL STUDY UPDATE
25th Mar 20207:00 amRNSHolding(s) in Company
23rd Mar 20207:00 amRNSMarket Update

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.